July 1st 2020EP. 1: Treatment After Progression on CDK 4/6i in mBC
July 1st 2020EP. 2: SOLAR-1 Trial in Metastatic Breast Cancer
July 1st 2020EP. 3: Payer Perspective of Coverage on Cancer Therapies
July 1st 2020EP. 4: Payer Coverage on Repeat Biopsy in mBC
July 1st 2020EP. 5: Advantages of Oral Taxanes in mBC
July 1st 2020EP. 6: Compliance and Adherence to Therapy in mBC
July 1st 2020EP. 7: Payer Coverage of IV Versus Oral Therapy in mBC
July 1st 2020EP. 8: Evolving Treatment Landscape of R/R HER2+ mBC
July 1st 2020EP. 9: HER2CLIMB and NALA Trials: R/R HER2+ mBC
July 1st 2020EP. 10: SOPHIA Trial in R/R HER2+ mBC
July 1st 2020EP. 11: Sequencing of Therapy in R/R HER2+ mBC
July 1st 2020EP. 12: IMpassion130 Trial Data on PD-L1+ Tumors in TNBC
July 1st 2020EP. 13: Role of PARP Inhibition and I/O Therapy in TNBC
July 1st 2020EP. 14: Treatment Options in Metastatic TNBC
July 1st 2020EP. 15: Considerations for NGS Testing in mTNBC
July 1st 2020EP. 16: Assessing the Value of Personalized Treatment in mBC
July 1st 2020EP. 17: Closing Thoughts on Metastatic Breast Cancers
